Asparagine promotes cancer cell proliferation through use as an amino acid exchange factor

Nature Communications

Volumn 7, Issue , 2016, Pages

  Krall, Abigail S ^a   Xu, Shili ^a   Graeber, Thomas G ^a,b   Braas, Daniel ^a,b   Christofk, Heather R ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; ASPARAGINE; HISTIDINE; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; SHORT HAIRPIN RNA; ASPARTATE AMMONIA LIGASE; CULTURE MEDIUM; GLUTAMINE; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; NUCLEOTIDE; SERINE; TARGET OF RAPAMYCIN KINASE;

AMINO ACID; CANCER; CELLS AND CELL COMPONENTS; CONCENTRATION (COMPOSITION); ENZYME ACTIVITY; METABOLISM;

AMINO ACID TRANSPORT; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HELA CELL LINE; HUMAN; HUMAN CELL; NUCLEOTIDE METABOLISM; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; REGULATORY MECHANISM; BIOSYNTHESIS; CHEMISTRY; CULTURE MEDIUM; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PHARMACOLOGY; SIGNAL TRANSDUCTION; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

ARGININE; ASPARAGINE; ASPARTATE-AMMONIA LIGASE; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; CELL PROLIFERATION; CULTURE MEDIA; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTAMINE; HELA CELLS; HISTIDINE; HUMANS; METABOLIC NETWORKS AND PATHWAYS; MULTIPROTEIN COMPLEXES; NUCLEOTIDES; SERINE; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84964670673     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms11457     Document Type: Article

References (32)

1. DeBerardinis, R. J. et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc. Natl Acad. Sci. USA 104, 19345-19350 (2007).
2. Chan, W. K. et al. The glutaminase activity of L-asparaginase is not required for anticancer activity against ASNS-negative cells. Blood 123, 3596-3606 (2014).
3. Lorenzi, P. L. et al. Asparagine synthetase is a predictive biomarker of L-asparaginase activity in ovarian cancer cell lines. Mol. Cancer Ther. 7, 3123-3128 (2008).
4. Holleman, A. et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukaemia cells and response to treatment. N. Engl. J. Med. 351, 533-542 (2004).
5. Zhang, J. et al. Asparagine plays a critical role in regulating cellular adaptation to glutamine depletion. Mol. Cell 56, 205-218 (2014).
6. Hettmer, S. et al. Functional genomic screening reveals asparagine dependence as a metabolic vulnerability in sarcoma. Elife 4, e09436 (2015).
7. Gong, S. S., Guerrini, L. & Basilico, C. Regulation of asparagine synthetase gene expression by amino acid starvation. Mol. Cell. Biol. 11, 6059-6066 (1991).
8. Hutson, R. G. & Kilberg, M. S. Cloning of rat asparagine synthetase and specificity of the amino acid-dependent control of its mRNA content. Biochem. J. 304(Pt 3): 745-750 (1994).
9. Ye, J. et al. The GCN2-ATF4 pathway is critical for tumour cell survival and proliferation in response to nutrient deprivation. EMBO J. 29, 2082-2096 (2010).
10. Gross, M. I. et al. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol. Cancer Ther. 13, 890-901 (2014).
11. Robinson, M. M. et al. Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES). Biochem. J. 406, 407-414 (2007).
12. Wang, J. B. et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 18, 207-219 (2010).
13. Tardito, S. et al. Glutamine synthetase activity fuels nucleotide biosynthesis and supports growth of glutamine-restricted glioblastoma. Nat. Cell Biol. 17, 1556-1568 (2015).
14. Nicklin, P. et al. Bidirectional transport of amino acids regulates mTOR and autophagy. Cell 136, 521-534 (2009).
15. Duran, R. V. et al. Glutaminolysis activates Rag-mTORC1 signalling. Mol. Cell 47, 349-358 (2012).
16. Jewell, J. L. et al. Differential regulation of mTORC1 by leucine and glutamine. Science 347, 194-198 (2015).
17. Bar-Peled, L., Schweitzer, L. D., Zoncu, R. & Sabatini, D. M. Ragulator is a GEF for the rag GTPases that signal amino acid levels to mTORC1. Cell 150, 1196-1208 (2012).
18. Zoncu, R., Efeyan, A. & Sabatini, D. M. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 12, 21-35 (2011).
19. Wang, S. et al. Metabolism. Lysosomal amino acid transporter SLC38A9 signals arginine sufficiency to mTORC1. Science 347, 188-194 (2015).
20. Dibble, C. C. & Manning, B. D. Signal integration by mTORC1 coordinates nutrient input with biosynthetic output. Nat. Cell Biol. 15, 555-564 (2013).
21. Ma, X. M. & Blenis, J. Molecular mechanisms of mTOR-mediated translational control. Nat. Rev. Mol. Cell Biol. 10, 307-318 (2009).
22. Yamaguchi, S. et al. ATF4-mediated induction of 4E-BP1 contributes to pancreatic beta cell survival under endoplasmic reticulum stress. Cell Metab. 7, 269-276 (2008).
23. Han, J. et al. ER-stress-induced transcriptional regulation increases protein synthesis leading to cell death. Nat. Cell Biol. 15, 481-490 (2013).
24. Maddocks, O. D., Labuschagne, C. F., Adams, P. D. & Vousden, K. H. Serine metabolism supports the methionine cycle and DNA/RNA methylation through de novo ATP synthesis in cancer cells. Mol. Cell 61, 210-221 (2016).
25. Ben-Sahra, I., Howell, J. J., Asara, J. M. & Manning, B. D. Stimulation of de novo pyrimidine synthesis by growth signalling through mTOR and S6K1. Science 339, 1323-1328 (2013).
26. Cunningham, J. T., Moreno, M. V., Lodi, A., Ronen, S. M. & Ruggero, D. Protein and nucleotide biosynthesis are coupled by a single rate-limiting enzyme, PRPS2, to drive cancer. Cell 157, 1088-1103 (2014).
27. Stegink, L. D. et al. Plasma amino acid concentrations and amino acid ratios in normal adults and adults heterozygous for phenylketonuria ingesting a hamburger and milk shake meal. Am. J. Clin. Nutr. 53, 670-675 (1991).
28. Braas, D. et al. Metabolomics strategy reveals subpopulation of liposarcomas sensitive to gemcitabine treatment. Cancer Discov. 2, 1109-1117 (2012).
29. Smith, K. B. et al. Novel dedifferentiated liposarcoma xenograft models reveal PTEN downregulation as a malignant signature and response to PI3K pathway inhibition. Am. J. Pathol. 182, 1400-1411 (2013).
30. Moseley, H. N. Correcting for the effects of natural abundance in stable isotope resolved metabolomics experiments involving ultra-high resolution mass spectrometry. BMC Bioinformatics 11, 139 (2010).
31. Abel, E. V. et al. Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3. J. Clin. Invest. 123, 2155-2168 (2013).
32. Basile, K. J. et al. In vivo MAPK reporting reveals the heterogeneity in tumoral selection of resistance to RAF inhibitors. Cancer Res. 73, 7101-7110 (2013).